Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/27—Growth hormone [GH] (Somatotropin)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Definitions

• hGH growth hormone
• the invention relates to the use of human growth hormone (hGH, GH) for the manufacture of medicaments for the treatment of sexual dysfunctions of both sexes and methods for their treatment.
• hGH human growth hormone
• Sexual dysfunctions include e.g. lack or loss of libido, orgasmic disorders, insufficient lubrication and erectile dysfunction (ED).
• ED erectile dysfunction
• vascular (arterial, venous), psychogenic, neurogenic, hormonal, drug-induced and cavernous sexual dysfunctions are distinguished.
• ED therapy in men offers a variety of treatments. These include oral, topical, intracavernous, intraurethral, or combinations of pharmaceuticals, which, however, are not causal therapy, but are aimed at direct or indirect relaxation (relaxation) of the smooth cavernous muscles and the penile arteries. In connection with the resulting increase in blood flow, there is a penile erection. Furthermore, the vacuum pump, the arterial shunt procedures, venous blocking operations and penile prosthesis implantations are also used. Until the introduction of Sildenafil (Viagra®), mainly vasoactive substances to be administered intracavernously were used therapeutically. At the moment sildenafil is used as so-called "first line therapy", with the exclusion of existing contraindications. This too
• PDE5 CONFIRMATION COPY oral phosphodiesterase 5 inhibitor
• cGMP cyclic guanosine monophosphate
• second messenger an intracellular messenger
• the object of the invention was therefore to provide the possibility of a new therapy for sexual dysfunction in men and women.
• growth hormone plays an essential role in sexual arousal, since an enormous unexpected increase in this hormone was found at the beginning of sexual arousal.
• the invention therefore relates to the use of hGH for the production of medicaments for the treatment of sexual functional disorders in men and women, such as, for example, a lack or loss of libido, orgasmic disorders, inadequate lubrication and erectile dysfunction, and the therapy of the functional disorders mentioned.
• Another object of the invention is the use of hGH for the therapy of these functional disorders in a synergistic combination with active ingredients which lead to GH stimulation, have a GH-analogous effect or promote IGF-I release.
• FIG. 1 shows the mean values and standard deviations of the
• hGH Growth hormone
• Figure 3 shows the mean values and standard deviations of the dose-dependent decrease in tissue tension (relaxation in%) of 12 human corpus cavernosum strips after application of recombinant hGH.
• Figure 4 shows the mean and standard deviations of the dose-dependent increase in cyclic guanosine monophosphate (cGMP) from 3 human corpus cavernosum strips after incubation with recombinant hGH or nitroprusside sodium (SNP). Incubations were only carried out with SNP from a concentration of 0.01 nmol. For this reason, the value at 0.0001 nmol is missing for SNP.
• cGMP cyclic guanosine monophosphate
• the aim of this new examination method is to improve diagnostics and therapy (use of the body's own substances and thus causal therapy) in patients with sexual dysfunction.
• peripheral and cavernous hGH concentrations showed no significant differences in all penile erection phases.
• hGH as a centrally formed hormone, plays a crucial role in sexual function (sexual arousal) and especially in penile erection. Furthermore, it has been shown that the peripheral reaction mediated by hGH induces an increase in cGMP in the CC, with which the relaxation of the CC is physiologically associated with the resulting erection. Due to the anatomical similarities in the structure of the penis and clitoris and the physiological agreement regarding sexual arousal (e.g.
• hGH insulin like growth factor I
• body growth substitution in the case of short stature due to hGH deficiency
• protein metabolism possibly indication for cachexia, severe burn injuries, and possible abuse as an anabolic steroid.
• IGF-I insulin like growth factor I
• An important mediating role in the action induced by hGH is attributed to this polypeptide (IGF-I) (Merimee, TJ and Grant, MB: Growth hormone and its disorders.
• NO-cGMP pathway is also assigned a very important positive meaning in the development of penile erection (Burnett, AL et al .: Nitric oxide: a Physiologie mediator of penile erection. Science, 257: 905, 1993). Also new knowledge from animal experiments in rats could show that there is an increase in NOS when hGH is substituted
• Nerves nitrogen oxide synthase
• nerves (nitrogen oxide synthase) (generate NO) in the CC and dorsal penile nerves came after weeks before neurogenic damage was initiated (Jung, GW et al .: Growth hormone enhances regeneration of nitric oxide synthase-containing penile nerves after cavernous nerve neurotomy in rats. J Urol, 160: 1899-1904, 1998).
• the patent W098 / 42361 Human erectile dysfunction and methods of treatment is derived from these results and describes the indication of hGH therapy for the prevention and treatment of neurogenic erectile dysfunction of various causes (condition after extensive pelvic surgery or pelvic trauma, diabetes, alcoholism and age ).
• a peripheral blood sample is first taken to determine the basal hGH concentration, regardless of the underlying etiology (s). In the same session, then takes place under sexual stimulation (audiovisual, tactile) another blood sample with detection of the stimulated hGH concentration. If there is insufficient or no response to sexual stimulation (e.g. lubrication, penile erection) and there is insufficient increase in the hGH concentration, continuous, closely controlled therapy with hGH should be carried out for a longer period (e.g. 2-6 months).
• compositions suitable for therapy are solid or liquid administration forms for oral administration, such as tablets, capsules or emulsions, parenteral administration forms for injection or for non-invasive administration, or transdermal topical systems such as plasters,
• the amount administered for a successful therapy is 0.01 to 500 mg per dose unit, preferably between 0, 1 and 100 mg.
• An improvement in the success of the therapy can be achieved by combination drugs containing, in addition to hGH in a synergistic combination, active ingredients which lead to GH stimulation, have a GH-analogous effect or promote IGF-I release.
• active ingredients do not necessarily have to be combined in one pharmaceutical, but can also be administered in separate suitable galenical preparations next to one another or separately according to a therapeutic regimen.
• combinations of several of the classes of active substances mentioned can of course also be used for use or therapy according to the invention.
• the person skilled in the art is familiar with the suitable active substances mentioned as possible combinations, which lead to GH stimulation.
• suitable active substances mentioned include arginine, alpha 1 and alpha 2 agonists such as clonidine, norepinephrine or salbutamol, glucagon, pyridostigmine, galanin, GH-releasing hormone, NPY (neuropeptide Y) and dopamine agonists such as apomorphine, quinpirole or cabergoline.
• Suitable active substances which have a GH-analogous effect are, for example, GHRP (Growth Hormone Releasing Hexapeptide, Hexarelin), GH Releasing Peptide 1, 2, 6 and non-peptide-agonists of growth hormone releasing peptides such as MK 0677, EP 51389 (2-methylalanyl-2- methyl-D-tryptophyl-2-methyl -) - D-tryptophanamide), L 692429 (3-amino-3-methyl-N - [(3R) -2,3,4,5-tetrahydro-2-oxo-1 - [[2 '- (1 H-tetrazol-5-yl) [1, 1'-biphenyl] -4-yl] methyl] -1 H-1-benzazepin-3-yl] butanamide), or L 692585 (3 - [[(2R) -2-Hydroxypropyl] amino] -3-methyl-N - [(
• Suitable active ingredients that promote IGF-I release include cannabinoids such as.
• cannabinoids such as.
• B. HU-210 (3- (1, 1-dimethylheptyl) -6a, 7, 10, 10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo [b, d] pyran-9-methanol) or serotonin receptor agonists such as 8-OH DPAT (8-hydroxy-2- (dipropylamino) tetralin), or SC 53116 (4-amino-5-chloro-N - [[(1 S, 7aS) - hexahydro-1 H-pyrrolizin-1-yl ] methyl] -2-methoxy-benzamide).

Applications Claiming Priority (3)

Publications (1)

Family

ID=7911578

Family Applications (1)

Country Status (6)

Families Citing this family (5)

Family Cites Families (2)

• 2000
  • 2000-06-15 CA CA002377339A patent/CA2377339A1/en not_active Abandoned
  • 2000-06-15 JP JP2001504391A patent/JP2003502379A/ja active Pending
  • 2000-06-15 EP EP00949187A patent/EP1207902A2/de not_active Withdrawn
  • 2000-06-15 WO PCT/EP2000/005517 patent/WO2000078328A2/de not_active Application Discontinuation
  • 2000-06-15 AU AU62635/00A patent/AU781842B2/en not_active Ceased
  • 2000-06-15 NZ NZ516223A patent/NZ516223A/en unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events